4.7 Article

A Mendelian randomization analysis of circulating lipid traits and breast cancer risk

Journal

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Volume 49, Issue 4, Pages 1117-1131

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/ije/dyz242

Keywords

Breast cancer; lipids; cholesterol; genetics; Mendelian randomization; instrumental variable; epidemiology

Funding

  1. National Cancer Institute at the National Institutes of Health [R37CA070867]
  2. National Institutes of Health [R25CA160056, CA128978, R01 CA77398, CA116167, CA176785, CA192393, CA63464, CA54281, CA098758, CA132839, R01CA100374, P30 CA68485, UM1 CA164920]
  3. Cancer Research UK [C1287/A16563, C1287/A12014, C1287/A10118, C1287/A10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565, C490/A10124, C490/A16561]
  4. European Community's Seventh Framework Programme [223175, HEALTH-F2-2009-223175]
  5. Post-Cancer GWAS initiative [1U19 CA148537, 1U19 CA148065, 1U19 CA148112]
  6. Department of Defense [W81XWH-10-1-0341]
  7. Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer
  8. Komen Foundation for the Cure
  9. Breast Cancer Research Foundation
  10. Ovarian Cancer Research Fund
  11. NIH [U19 CA148065]
  12. Cancer UK Grant [C1287/A16563]
  13. Government of Canada through Genome Canada
  14. Canadian Institutes of Health Research [GPH-129344]
  15. Ministere de l'Economie, Science et Innovation du Quebec through Genome Quebec
  16. Quebec Breast Cancer Foundation
  17. National Institutes of Health (USA) [UM1 CA164920]
  18. National Health and Medical Research Council of Australia
  19. New South Wales Cancer Council
  20. Victorian Health Promotion Foundation (Australia)
  21. Victorian Breast Cancer Research Consortium
  22. Dutch Cancer Society [NKI 2007-3839, 2009 4363, RUL 1997-1505, DDHK 2004-3124, DDHK 2009-4318]
  23. BBMRI-NL
  24. Dutch government [NWO 184.021.007]
  25. ELAN-Fond of the University Hospital of Erlangen
  26. Cancer Research UK
  27. Breakthrough Breast Cancer
  28. NHS
  29. National Cancer Research Network (NCRN)
  30. NIHR Comprehensive Biomedical Research Centre
  31. Guy's & St Thomas' NHS Foundation Trust
  32. King's College London, UK
  33. Oxford Biomedical Research Centre
  34. Dietmar-Hopp Foundation
  35. Fondation de France
  36. Institut National du Cancer (INCa)
  37. Ligue Nationale contre le Cancer
  38. Agence Nationale de Securite Sanitaire (ANSES)
  39. Agence Nationale de la Recherche (ANR)
  40. Chief Physician Johan Boserup and Lise Boserup Fund
  41. Danish Medical Research Council
  42. Herlev Hospital
  43. Spanish Network on Rare Diseases (CIBERER)
  44. Asociacion Espanola Contra el Cancer
  45. Fondo de Investigacion Sanitario [PI11/00923, PI12/00070]
  46. Instituto de Salud Carlos III
  47. California Breast Cancer Act of 1993
  48. California Breast Cancer Research Fund [97-10500]
  49. California Department of Public Health as part of the statewide cancer reporting programme [103885]
  50. Lon V Smith Foundation [LVS39420]
  51. Baden Wurttemberg Ministry of Science, Research and Arts
  52. German Cancer Aid (Deutsche Krebshilfe)
  53. Deutsche Krebshilfe [107 352]
  54. Federal Ministry of Education and Research (BMBF) Germany [01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114, 01KH0402]
  55. Robert Bosch Foundation, Stuttgart
  56. Deutsches Krebsforschungszentrum (DKFZ), Heidelberg
  57. Institute for Prevention and Occupational Medicine of the German Social Accident Insurance
  58. Institute of the RuhrUniversity Bochum (IPA)
  59. Department of Internal Medicine
  60. Evangelische Kliniken Bonn gGmbH
  61. Johanniter Krankenhaus Bonn, Germany
  62. Finnish Cancer Society
  63. Sigrid Juselius Foundation
  64. Rudolf Bartling Foundation
  65. Stockholm County Council
  66. Karolinska Institutet
  67. Swedish Cancer Society
  68. Gustav V Jubilee foundation
  69. Bert von Kantzows Foundation
  70. special Government Funding (EVO) of Kuopio University Hospital grants
  71. Cancer Fund of North Savo
  72. Academy of Finland
  73. University of Eastern Finland
  74. National Breast Cancer Foundation
  75. National Health and Medical Research Council (NHMRC)
  76. Queensland Cancer Fund
  77. Cancer Council of New South Wales
  78. Cancer Council of Victoria
  79. Cancer Council of Tasmania
  80. Cancer Council of South Australia
  81. Cancer Foundation of Western Australia
  82. Stichting tegen Kanker [232-2008, 196-2010]
  83. FWO
  84. ERC consolidator grant
  85. Deutsche Krebshilfe e.V. [70-2892-BR I, 106332, 108253, 108419]
  86. Hamburg Cancer Society
  87. German Cancer Research Center (DKFZ)
  88. Italian Association for Cancer Research (AIRC)
  89. Fondazione IRCCS Istituto Nazionale Tumori
  90. National Institutes of Health Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]
  91. VicHealth
  92. Australian NHMRC [209057, 251553, 504711]
  93. Canadian Institutes of Health Research for the 'CIHR Team in Familial Risks of Breast Cancer' program [CRN-87521]
  94. Ministry of Economic Development, Innovation and Export Trade [PSR-SIIRI-701]
  95. Norwegian Research council [155218/V40, 175240/S10, FUGE-NFR 181600/V11]
  96. Finnish Cancer Foundation
  97. Academy of Finland [250083, 122715, 266528]
  98. Academy of Finland (Center of Excellence) [251314]
  99. University of Oulu
  100. University of Oulu Support Foundation
  101. special Governmental EVO funds for Oulu University Hospital-based research activities
  102. Biobanking and Biomolecular Resources Research Infrastructure [BBMRI-NL CP16]
  103. National Cancer Institute, Department of Health and Human Services, USA
  104. Marit and Hans Rausings Initiative Against Breast Cancer
  105. Agency for Science, Technology and Research of Singapore (A*STAR)
  106. US National Institute of Health
  107. Susan G Komen Breast Cancer Foundation
  108. Sheffield Experimental Cancer Medicine Centre
  109. Breast Cancer Now Tissue Bank
  110. UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge
  111. DKFZ
  112. Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201]
  113. Hellenic Cooperative Oncology Group research grant [HR R_BG/04]
  114. Greek General Secretary for Research and Technology (GSRT) Program
  115. European Union (European Social Fund -ESF)
  116. Greek national funds through the Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF) -ARISTEIA
  117. Breast Cancer Now
  118. Institute of Cancer Research (ICR), London
  119. Helmholtz Society
  120. Helsinki University Central Hospital Research Fund
  121. Cancer Council Victoria
  122. [PSRSIIRI-701]
  123. [KULPFV/10/016-SymBioSysII]
  124. [PBZ_KBN_122/P05/2004]

Ask authors/readers for more resources

Background: Conventional epidemiologic studies have evaluated associations between circulating lipid levels and breast cancer risk, but results have been inconsistent. As Mendelian randomization analyses may provide evidence for causal inference, we sought to evaluate potentially unbiased associations between breast cancer risk and four genetically predicted lipid traits. Methods: Previous genome-wide association studies (GWAS) have identified 164 discrete variants associated with high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), triglycerides and total cholesterol. We used 162 of these unique variants to construct weighted genetic scores (wGSs) for a total of 101 424 breast cancer cases and 80 253 controls of European ancestry from the Breast Cancer Association Consortium (BCAC). Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for associations between per standard deviation increase in genetically predicted lipid traits and breast cancer risk. Additional Mendelian randomization analysis approaches and sensitivity analyses were conducted to assess pleiotropy and instrument validity. Results: Corresponding to approximately 15 mg/dL, one standard deviation increase in genetically predicted HDL-C was associated with a 12% increased breast cancer risk (OR: 1.12, 95% CI: 1.08-1.16). Findings were consistent after adjustment for breast cancer risk factors and were robust in several sensitivity analyses. Associations with genetically predicted triglycerides and total cholesterol were inconsistent, and no association for genetically predicted LDL-C was observed. Conclusions: This study provides strong evidence that circulating HDL-C may be associated with an increased risk of breast cancer, whereas LDL-C may not be related to breast cancer risk.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available